Product Description: NVP-TAE 226 (TAE226) is a potent and ATP-competitive dual FAK and IGF-1R inhibitor with IC50s of 5.5 nM and 140 nM, respectively. NVP-TAE 226 (TAE226) also effectively inhibits Pyk2 and insulin receptor (InsR) with IC50s of 3.5 nM and 44 nM, respectively[1][2].
Applications: Cancer-Kinase/protease
Formula: C23H25ClN6O3
References: [1]Liu TJ, et al. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther, 2007, 6(4), 1357-1367./[2]Delimont D, et al. Laminin α2-mediated focal adhesion kinase activation triggers Alport glomerular pathogenesis. PLoS One. 2014 Jun 10;9(6):e99083./[3]Lietha D, et al. Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation. PLoS One. 2008;3(11):e3800.
CAS Number: 761437-28-9
Molecular Weight: 468.94
Compound Purity: 99.77
Research Area: Cancer; Endocrinology
Solubility: DMSO : 11.11 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Apoptosis;FAK;IGF-1R;Insulin Receptor;Pyk2
Deutsch
English
